910114-63-5

Basic information

• Product Name: Carbamimidothioic acid, [[[(4-fluorophenyl)methyl]amino]carbonyl]-,methyl ester
• CAS NO: 910114-63-5
• Molecular Formula: C10H12FN3OS
• Molecular Weight: 241.289
• Mol File: 910114-63-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamimidothioic acid, [[[(4-fluorophenyl)methyl]amino]carbonyl]-,methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamimidothioic acid, [[[(4-fluorophenyl)methyl]amino]carbonyl]-,methyl ester(910114-63-5)
• EPA Substance Registry System: Carbamimidothioic acid, [[[(4-fluorophenyl)methyl]amino]carbonyl]-,methyl ester(910114-63-5)

Safety Data

• Hazardous Substances Data: 910114-63-5(Hazardous Substances Data)

Upstream product

• 140-75-0 para-fluorobenzylamine 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 132740-43-3 4-fluorobenzylisocyanate 
• 867-44-7 S-Methylisothiourea sulfate 
• 14527-26-5 2-methylisothiourea sulphate 

Downstream Products

• 910114-64-6 5-(methylthio)-3,7-dioxo-1-(4-fluorobenzyl)-2-oxa-4,6,8-triazanon-4-en-9-oic acid methyl ester 
• 910114-06-6 N-{2-[5-(4-fluoro-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5]triazin-2-ylamino]-ethyl}-N'-amino-guanidine 
• 910114-79-3 [5-(4-fluoro-benzyl)-1-(4-methoxy-benzyl)-4,6-dioxo-1,4,5,6-tetrahydro-[1,3,5]triazin-2-ylamino]-acetic acid 
• 910114-66-8 3-(4-fluorobenzyl)-1-(4-methoxybenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dione 
• 910114-67-9 6-(2-aminoethylamino)-3-(4-fluorobenzyl)-1-(4-methoxybenzyl)-1,3,5-triazine-2,4(1H,3H)-dione 
• 911368-93-9 3-(4-fluoro-benzyl)-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione hydrochloride 
• 910114-65-7 3-(4-fluorobenzyl)-6-(methylthio)-1,3,5-triazine-2,4(1H,3H)-dione 
• 910114-64-6 5-(methylthio)-3,7-dioxo-1-(4-fluorobenzyl)-2-oxa-4,6,8-triazanon-4-en-9-oic acid methyl ester 

Relevant articles and documents

T-type calcium channel inhibitor

The present invention addresses the problem of providing novel compounds that have T-type voltage-gated calcium channel-blocking activity and are useful particularly in treating pain, chronic kidney disease, and atrial fibrillation. Provided are novel tri

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, L2, and Q are defined herein.

Triazinediones as prokineticin 1 receptor antagonists. Part 1: SAR, synthesis and biological evaluation

A series of guanidine triazinediones were identified as potent PK1 receptor antagonists. A compound in this series inhibited the PK1 invoked prosecretory response in rat ileum tissue.